Skip to content
Buy This GLP
← Research
Safety

Can You Mix Your Own Semaglutide? Twenty People Got 15 Steps of 34 Right

Gray-market peptide sites ship a powder and nothing else. Researchers watched twenty adults attempt the 34 steps that turn it into a dose.

Wesley Jenkins8 min read
34 steps from vial to injection15 completed correctly, on averageErrors seen: wrong dose, needle sticks, infection risk.20 participants. Standard deviation on that mean: 50%.Gray-market peptide supply, not prescribed telehealth.

You can, and the only study that watched people try recorded 15 correct steps out of 34. Twenty adults were handed semaglutide vials, diluent and injection supplies, then scored against every step the process requires [1]. They were allowed to look up whatever guidance they wanted online. The errors observed were the consequential kind: a wrong dose, a needle-stick injury, contamination capable of causing infection. The price gap that pulls people toward this route is set out in what a month actually costs.

What “mixing your own” means

Two markets are sold under similar words and only one of them ships a powder. A prescribed seller dispenses a prefilled pen, or a vial with syringes and written directions. A gray-market peptide site takes payment without a prescription and sends the vial alone.

Reconstitution is the step that separates the two. The buyer works out a concentration, draws a volume against that concentration, and keeps the whole sequence sterile. Each of those is an opportunity for a tenfold dosing error. None of them arises when a pharmacy ships a labeled syringe, which is the distinction drawn in the 503A and 503B explainer.

What happened when people tried

Thirty-four discrete steps were scored, from opening the vial to disposing of the needle. Participants completed a mean of 15 of them, about 44%. Confidence ratings were low before the attempt and stayed low afterwards, so nobody left the room believing they had done it right.

The participants were students and older adults recruited for a demonstration. They were not people who had decided to buy peptides, and that cuts both ways. A motivated buyer may work harder at the instructions. That buyer is also alone, at home, unobserved, and may not have been sent the correct diluent.

What is in the vial before anyone mixes it

Preparation errors assume the product is what the label says. Researchers ordered semaglutide from six no-prescription sellers and put what arrived through a laboratory [2]. Three orders were never delivered at all. Measured purity in the three vials that did arrive ran from 7.7% to 14.37%, against 99% claimed on the labels.

Semaglutide content exceeded the labeled amount by 28.56% to 38.69%, which is a separate assay pointing the other way. No viable microorganisms were found. Endotoxin was present in every sample, at 2.1645 to 8.9511 EU/mg, and sterilizing a product does not remove what dead bacteria left behind. What that means for a dose drawn by hand is covered in dosing from a vial.

Compounded product is a different question again

A manufacturer-run analysis compared follow-on and compounded peptides against the originator products [3]. The copies carried distinct impurity profiles: amino acid deletions, additions, and impurities the analysis could not identify. Under light exposure, compounded semaglutide differed on strength, total impurities and high-molecular-weight protein.

Every author on that paper is an employee and shareholder of the company that makes both originators. The chemistry is not thereby wrong, and the provenance is recorded here rather than omitted. The same test applies to what the B12 is doing in a compounded vial.

The rule this desk applies

A price may be compared against another price only when both buy the same thing. A vial shipped without supplies, labeling or instructions is not a dispensed prescription. The two are never ranked against each other here.

One question separates the markets and it is easy to ask. If nobody requires a prescription before taking the money, nobody has checked the product, the dose or the delivery. What turned up when one such product was cultured is in the stool culture that grew something else.

Frequently asked

Can you mix your own semaglutide at home?
It is physically possible and the recorded success rate is poor. Twenty adults given vials, diluent and supplies completed a mean of 15 of 34 required steps correctly, with errors capable of producing a wrong dose, a needle-stick injury or an infection.
Does this apply to compounded semaglutide from a telehealth provider?
It does not. This study concerns gray-market peptide sellers who ship no syringes, no diluent guidance and no instructions. Prescribed sellers dispense a pen or a vial with supplies and directions.
What was actually in the no-prescription vials?
Measured purity ran from 7.7% to 14.37% against 99% claimed on the labels, semaglutide content exceeded the labeled amount by 28.56% to 38.69%, and endotoxin was detected in every sample.
Do all the orders arrive?
Three of six test purchases were never delivered. The money was taken and nothing shipped, so for half the orders the product quality question never arose.
Is compounded product free of these impurity problems?
Not established either way. A manufacturer-run analysis found distinct impurity profiles in compounded and follow-on peptides, and no study has shown those differences make patients ill.

Sources

  1. [1] Sedensky A, Nuzi K, Nolan L, Belcourt J, White CM (2026). Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription Public Health Reports. PMID 42541373
  2. [2] Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, et al. (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study Journal of Medical Internet Research. PMID 39509151
  3. [3] Kopp KL, et al. (2026). Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists Pharmaceutical Research. PMID 42533250

More in Safety